[{"edinetCode":"E22024","endDate":"2017\/12\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":15.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":8157850.0,"sharesOwendPercent":0.3106,"outstandingShares":null,"numberOfSubsidiary":1.0,"bps":76.14,"equityRatio":0.695,"cashAndCashEquivalents":2132677000.0,"assets":2877489000.0,"currentAssets":2515588000.0,"fixedAsset":361901000.0,"tangibleFixedAssets":15087000.0,"intangibleFixedAssets":330343000.0,"investmentAndOtherAssets":16470000.0,"liabilities":781620000.0,"currentLiabilities":156270000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":625350000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":600000000.0,"netAsset":2095869000.0,"capitalStock":1999302000.0,"capital":3365279000.0,"capitalSurplus":3354653000.0,"accumulatedEarnings":-4720630000.0,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":254028000.0,"costOfSales":7304000.0,"grossProfit":246724000.0,"sgaExpenses":880431000.0,"salaryAndBenefit":null,"depreciationAndSGA":1614000.0,"RDExpenses":603320000.0,"operatingIncome":-633707000.0,"nonOperatingIncome":1068000.0,"nonOperatingExpenses":36265000.0,"interestExpense":5402000.0,"ordinaryProfit":-668904000.0,"extraordinaryGain":103060000.0,"extraordinaryLoss":1040000000.0,"incomeBeforeTax":-1605843000.0,"incomeTaxes":1840000.0,"netIncome":-1607683000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-1563497000.0,"comprehensiveIncome":-1607683000.0,"eps":-59.89,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-797215000.0,"depreciationAndCashflowFromOperatingActivities":45118000.0,"cashFlowFromInvestingActivities":-763123000.0,"cashFlowFromFinancialActivities":1406969000.0,"changesInCashAndCashEquivalents":-159257000.0,"列1":"asr","submitDate":"2018\/3\/29","stockCode":4576,"accountingYear":"第20期（自　平成29年１月１日　至　平成29年12月31日）","accountingYearStart":"2017\/1\/1","accountingYearEnd":"2017\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E22024","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":34,"settlementDate":"2022\/12\/31","submitterName":"株式会社デ・ウエスタン・セラピテクス研究所","submitterNameEnglish":"D.Western Therapeutics Institute, Inc.","submitterNameKana":"カブシキガイシャデウエスタンセラピテクスケンキュウジョ","location":"名古屋市中区錦一丁目１８番１１号","industory":"医薬品","corporateNumber":5180000000000.0},{"edinetCode":"E22024","endDate":"2018\/12\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":17.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":8301500.0,"sharesOwendPercent":0.3159,"outstandingShares":null,"numberOfSubsidiary":1.0,"bps":47.95,"equityRatio":0.608,"cashAndCashEquivalents":1584282000.0,"assets":2073753000.0,"currentAssets":1764457000.0,"fixedAsset":309296000.0,"tangibleFixedAssets":4825000.0,"intangibleFixedAssets":291944000.0,"investmentAndOtherAssets":12527000.0,"liabilities":773652000.0,"currentLiabilities":268302000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":120000000.0,"fixedLiabilities":505350000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":480000000.0,"netAsset":1300101000.0,"capitalStock":1259861000.0,"capital":34762000.0,"capitalSurplus":2133478000.0,"accumulatedEarnings":-908379000.0,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":292924000.0,"costOfSales":13592000.0,"grossProfit":279332000.0,"sgaExpenses":1065666000.0,"salaryAndBenefit":null,"depreciationAndSGA":2768000.0,"RDExpenses":795258000.0,"operatingIncome":-786334000.0,"nonOperatingIncome":788000.0,"nonOperatingExpenses":11360000.0,"interestExpense":6359000.0,"ordinaryProfit":-796906000.0,"extraordinaryGain":1657000.0,"extraordinaryLoss":6820000.0,"incomeBeforeTax":-802069000.0,"incomeTaxes":1567000.0,"netIncome":-803636000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-748966000.0,"comprehensiveIncome":-803636000.0,"eps":-28.51,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-540333000.0,"depreciationAndCashflowFromOperatingActivities":51677000.0,"cashFlowFromInvestingActivities":-7775000.0,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":-548395000.0,"列1":"asr","submitDate":"2019\/3\/28","stockCode":4576,"accountingYear":"第21期（自　2018年１月１日　至　2018年12月31日）","accountingYearStart":"2018\/1\/1","accountingYearEnd":"2018\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E22024","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":34,"settlementDate":"2022\/12\/31","submitterName":"株式会社デ・ウエスタン・セラピテクス研究所","submitterNameEnglish":"D.Western Therapeutics Institute, Inc.","submitterNameKana":"カブシキガイシャデウエスタンセラピテクスケンキュウジョ","location":"名古屋市中区錦一丁目１８番１１号","industory":"医薬品","corporateNumber":5180000000000.0},{"edinetCode":"E22024","endDate":"2019\/3\/31","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.674,"cashAndCashEquivalents":null,"assets":2094428000.0,"currentAssets":1796141000.0,"fixedAsset":298287000.0,"tangibleFixedAssets":4323000.0,"intangibleFixedAssets":281435000.0,"investmentAndOtherAssets":12527000.0,"liabilities":650807000.0,"currentLiabilities":176807000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":120000000.0,"fixedLiabilities":474000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":450000000.0,"netAsset":1443620000.0,"capitalStock":1412487000.0,"capital":34762000.0,"capitalSurplus":2133478000.0,"accumulatedEarnings":-755753000.0,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":275650000.0,"costOfSales":3342000.0,"grossProfit":272308000.0,"sgaExpenses":126421000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":63944000.0,"operatingIncome":145886000.0,"nonOperatingIncome":51000.0,"nonOperatingExpenses":2020000.0,"interestExpense":1566000.0,"ordinaryProfit":143918000.0,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":143918000.0,"incomeTaxes":398000.0,"netIncome":143519000.0,"netIncomeAttributableToOwnersOfTheParentCompany":152625000.0,"comprehensiveIncome":143519000.0,"eps":5.81,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2019\/5\/15","stockCode":4576,"accountingYear":null,"accountingYearStart":"2019\/1\/1","accountingYearEnd":"2019\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E22024","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":34,"settlementDate":"2022\/12\/31","submitterName":"株式会社デ・ウエスタン・セラピテクス研究所","submitterNameEnglish":"D.Western Therapeutics Institute, Inc.","submitterNameKana":"カブシキガイシャデウエスタンセラピテクスケンキュウジョ","location":"名古屋市中区錦一丁目１８番１１号","industory":"医薬品","corporateNumber":5180000000000.0},{"edinetCode":"E22024","endDate":"2019\/6\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":8630400.0,"sharesOwendPercent":0.3284,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.684,"cashAndCashEquivalents":1580953000.0,"assets":2039451000.0,"currentAssets":1752173000.0,"fixedAsset":287277000.0,"tangibleFixedAssets":3822000.0,"intangibleFixedAssets":270927000.0,"investmentAndOtherAssets":12527000.0,"liabilities":618208000.0,"currentLiabilities":174208000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":120000000.0,"fixedLiabilities":444000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":420000000.0,"netAsset":1421242000.0,"capitalStock":1395185000.0,"capital":34762000.0,"capitalSurplus":2133478000.0,"accumulatedEarnings":-773056000.0,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":363214000.0,"costOfSales":6998000.0,"grossProfit":356216000.0,"sgaExpenses":229127000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":121115000.0,"operatingIncome":127088000.0,"nonOperatingIncome":484000.0,"nonOperatingExpenses":5633000.0,"interestExpense":3071000.0,"ordinaryProfit":121939000.0,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":121939000.0,"incomeTaxes":797000.0,"netIncome":121141000.0,"netIncomeAttributableToOwnersOfTheParentCompany":135323000.0,"comprehensiveIncome":121141000.0,"eps":5.15,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":158379000.0,"depreciationAndCashflowFromOperatingActivities":22018000.0,"cashFlowFromInvestingActivities":-100000000.0,"cashFlowFromFinancialActivities":-60000000.0,"changesInCashAndCashEquivalents":-3328000.0,"列1":"q2r","submitDate":"2019\/8\/9","stockCode":4576,"accountingYear":null,"accountingYearStart":"2019\/1\/1","accountingYearEnd":"2019\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E22024","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":34,"settlementDate":"2022\/12\/31","submitterName":"株式会社デ・ウエスタン・セラピテクス研究所","submitterNameEnglish":"D.Western Therapeutics Institute, Inc.","submitterNameKana":"カブシキガイシャデウエスタンセラピテクスケンキュウジョ","location":"名古屋市中区錦一丁目１８番１１号","industory":"医薬品","corporateNumber":5180000000000.0},{"edinetCode":"E22024","endDate":"2019\/9\/30","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.692,"cashAndCashEquivalents":null,"assets":1994205000.0,"currentAssets":1717937000.0,"fixedAsset":276268000.0,"tangibleFixedAssets":3321000.0,"intangibleFixedAssets":260419000.0,"investmentAndOtherAssets":12527000.0,"liabilities":595678000.0,"currentLiabilities":181678000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":120000000.0,"fixedLiabilities":414000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":390000000.0,"netAsset":1398527000.0,"capitalStock":1379810000.0,"capital":34762000.0,"capitalSurplus":2133478000.0,"accumulatedEarnings":-788430000.0,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":451815000.0,"costOfSales":16044000.0,"grossProfit":435770000.0,"sgaExpenses":328437000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":181260000.0,"operatingIncome":107333000.0,"nonOperatingIncome":569000.0,"nonOperatingExpenses":8280000.0,"interestExpense":4513000.0,"ordinaryProfit":99622000.0,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":99622000.0,"incomeTaxes":1196000.0,"netIncome":98426000.0,"netIncomeAttributableToOwnersOfTheParentCompany":119949000.0,"comprehensiveIncome":98426000.0,"eps":4.57,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2019\/11\/14","stockCode":4576,"accountingYear":null,"accountingYearStart":"2019\/1\/1","accountingYearEnd":"2019\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E22024","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":34,"settlementDate":"2022\/12\/31","submitterName":"株式会社デ・ウエスタン・セラピテクス研究所","submitterNameEnglish":"D.Western Therapeutics Institute, Inc.","submitterNameKana":"カブシキガイシャデウエスタンセラピテクスケンキュウジョ","location":"名古屋市中区錦一丁目１８番１１号","industory":"医薬品","corporateNumber":5180000000000.0},{"edinetCode":"E22024","endDate":"2019\/12\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":17.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":8807139.0,"sharesOwendPercent":0.3351,"outstandingShares":null,"numberOfSubsidiary":1.0,"bps":53.02,"equityRatio":0.703,"cashAndCashEquivalents":1540784000.0,"assets":1981349000.0,"currentAssets":1715782000.0,"fixedAsset":265567000.0,"tangibleFixedAssets":3128000.0,"intangibleFixedAssets":249911000.0,"investmentAndOtherAssets":12527000.0,"liabilities":573265000.0,"currentLiabilities":189265000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":120000000.0,"fixedLiabilities":384000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":360000000.0,"netAsset":1408083000.0,"capitalStock":1393065000.0,"capital":34762000.0,"capitalSurplus":2133478000.0,"accumulatedEarnings":-775176000.0,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":580527000.0,"costOfSales":25853000.0,"grossProfit":554674000.0,"sgaExpenses":437359000.0,"salaryAndBenefit":null,"depreciationAndSGA":1667000.0,"RDExpenses":249362000.0,"operatingIncome":117315000.0,"nonOperatingIncome":677000.0,"nonOperatingExpenses":8414000.0,"interestExpense":5875000.0,"ordinaryProfit":109578000.0,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":109578000.0,"incomeTaxes":1595000.0,"netIncome":107982000.0,"netIncomeAttributableToOwnersOfTheParentCompany":133203000.0,"comprehensiveIncome":107982000.0,"eps":5.07,"dilutedEps":null,"dividendPerShare":null,"per":128.0,"roe":0.1,"cashFlowFromOperatingActivities":175651000.0,"depreciationAndCashflowFromOperatingActivities":44192000.0,"cashFlowFromInvestingActivities":-100000000.0,"cashFlowFromFinancialActivities":-120000000.0,"changesInCashAndCashEquivalents":-43497000.0,"列1":"asr","submitDate":"2020\/3\/26","stockCode":4576,"accountingYear":"第22期（自　2019年１月１日　至　2019年12月31日）","accountingYearStart":"2019\/1\/1","accountingYearEnd":"2019\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E22024","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":34,"settlementDate":"2022\/12\/31","submitterName":"株式会社デ・ウエスタン・セラピテクス研究所","submitterNameEnglish":"D.Western Therapeutics Institute, Inc.","submitterNameKana":"カブシキガイシャデウエスタンセラピテクスケンキュウジョ","location":"名古屋市中区錦一丁目１８番１１号","industory":"医薬品","corporateNumber":5180000000000.0},{"edinetCode":"E22024","endDate":"2020\/3\/31","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.722,"cashAndCashEquivalents":null,"assets":1869187000.0,"currentAssets":1614398000.0,"fixedAsset":254788000.0,"tangibleFixedAssets":2845000.0,"intangibleFixedAssets":239415000.0,"investmentAndOtherAssets":12527000.0,"liabilities":514137000.0,"currentLiabilities":160137000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":120000000.0,"fixedLiabilities":354000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":330000000.0,"netAsset":1355049000.0,"capitalStock":1349488000.0,"capital":34762000.0,"capitalSurplus":2133478000.0,"accumulatedEarnings":-818752000.0,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":74589000.0,"costOfSales":2924000.0,"grossProfit":71665000.0,"sgaExpenses":121735000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":61977000.0,"operatingIncome":-50070000.0,"nonOperatingIncome":75000.0,"nonOperatingExpenses":2640000.0,"interestExpense":1268000.0,"ordinaryProfit":-52636000.0,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":-52636000.0,"incomeTaxes":398000.0,"netIncome":-53034000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-43576000.0,"comprehensiveIncome":-53034000.0,"eps":-1.66,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2020\/5\/14","stockCode":4576,"accountingYear":null,"accountingYearStart":"2020\/1\/1","accountingYearEnd":"2020\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E22024","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":34,"settlementDate":"2022\/12\/31","submitterName":"株式会社デ・ウエスタン・セラピテクス研究所","submitterNameEnglish":"D.Western Therapeutics Institute, Inc.","submitterNameKana":"カブシキガイシャデウエスタンセラピテクスケンキュウジョ","location":"名古屋市中区錦一丁目１８番１１号","industory":"医薬品","corporateNumber":5180000000000.0},{"edinetCode":"E22024","endDate":"2020\/6\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":8537400.0,"sharesOwendPercent":0.3244,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.73,"cashAndCashEquivalents":1398094000.0,"assets":1794889000.0,"currentAssets":1550889000.0,"fixedAsset":243999000.0,"tangibleFixedAssets":2874000.0,"intangibleFixedAssets":229317000.0,"investmentAndOtherAssets":11807000.0,"liabilities":485196000.0,"currentLiabilities":160798000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":120000000.0,"fixedLiabilities":324398000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":300000000.0,"netAsset":1309692000.0,"capitalStock":1309692000.0,"capital":41570000.0,"capitalSurplus":2140286000.0,"accumulatedEarnings":-872165000.0,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":151482000.0,"costOfSales":5595000.0,"grossProfit":145887000.0,"sgaExpenses":246764000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":123809000.0,"operatingIncome":-100877000.0,"nonOperatingIncome":573000.0,"nonOperatingExpenses":10906000.0,"interestExpense":2457000.0,"ordinaryProfit":-111210000.0,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":-111210000.0,"incomeTaxes":797000.0,"netIncome":-112007000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-96989000.0,"comprehensiveIncome":-112007000.0,"eps":-3.69,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-79985000.0,"depreciationAndCashflowFromOperatingActivities":21609000.0,"cashFlowFromInvestingActivities":-821000.0,"cashFlowFromFinancialActivities":-60000000.0,"changesInCashAndCashEquivalents":-142690000.0,"列1":"q2r","submitDate":"2020\/8\/13","stockCode":4576,"accountingYear":null,"accountingYearStart":"2020\/1\/1","accountingYearEnd":"2020\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E22024","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":34,"settlementDate":"2022\/12\/31","submitterName":"株式会社デ・ウエスタン・セラピテクス研究所","submitterNameEnglish":"D.Western Therapeutics Institute, Inc.","submitterNameKana":"カブシキガイシャデウエスタンセラピテクスケンキュウジョ","location":"名古屋市中区錦一丁目１８番１１号","industory":"医薬品","corporateNumber":5180000000000.0},{"edinetCode":"E22024","endDate":"2020\/9\/30","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.83,"cashAndCashEquivalents":null,"assets":2754098000.0,"currentAssets":2517713000.0,"fixedAsset":236384000.0,"tangibleFixedAssets":5602000.0,"intangibleFixedAssets":218786000.0,"investmentAndOtherAssets":11995000.0,"liabilities":465029000.0,"currentLiabilities":170034000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":120000000.0,"fixedLiabilities":294995000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":270000000.0,"netAsset":2289068000.0,"capitalStock":2286310000.0,"capital":556856000.0,"capitalSurplus":2655571000.0,"accumulatedEarnings":-926118000.0,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":240547000.0,"costOfSales":11363000.0,"grossProfit":229184000.0,"sgaExpenses":376880000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":184386000.0,"operatingIncome":-147696000.0,"nonOperatingIncome":2603000.0,"nonOperatingExpenses":19671000.0,"interestExpense":3579000.0,"ordinaryProfit":-164764000.0,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":-164764000.0,"incomeTaxes":1196000.0,"netIncome":-165960000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-150942000.0,"comprehensiveIncome":-165960000.0,"eps":-5.7,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2020\/11\/13","stockCode":4576,"accountingYear":null,"accountingYearStart":"2020\/1\/1","accountingYearEnd":"2020\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E22024","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":34,"settlementDate":"2022\/12\/31","submitterName":"株式会社デ・ウエスタン・セラピテクス研究所","submitterNameEnglish":"D.Western Therapeutics Institute, Inc.","submitterNameKana":"カブシキガイシャデウエスタンセラピテクスケンキュウジョ","location":"名古屋市中区錦一丁目１８番１１号","industory":"医薬品","corporateNumber":5180000000000.0},{"edinetCode":"E22024","endDate":"2020\/12\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":15.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":9178503.0,"sharesOwendPercent":0.3137,"outstandingShares":null,"numberOfSubsidiary":1.0,"bps":73.88,"equityRatio":0.789,"cashAndCashEquivalents":2308210000.0,"assets":2737711000.0,"currentAssets":2503284000.0,"fixedAsset":234426000.0,"tangibleFixedAssets":5292000.0,"intangibleFixedAssets":208254000.0,"investmentAndOtherAssets":20879000.0,"liabilities":573805000.0,"currentLiabilities":209805000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":120000000.0,"fixedLiabilities":364000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":340000000.0,"netAsset":2163905000.0,"capitalStock":2161147000.0,"capital":556856000.0,"capitalSurplus":2655571000.0,"accumulatedEarnings":-1051280000.0,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":355586000.0,"costOfSales":17019000.0,"grossProfit":338566000.0,"sgaExpenses":604246000.0,"salaryAndBenefit":null,"depreciationAndSGA":1395000.0,"RDExpenses":350535000.0,"operatingIncome":-265679000.0,"nonOperatingIncome":2611000.0,"nonOperatingExpenses":26459000.0,"interestExpense":4728000.0,"ordinaryProfit":-289527000.0,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":-289527000.0,"incomeTaxes":1595000.0,"netIncome":-291123000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-276104000.0,"comprehensiveIncome":-291123000.0,"eps":-10.16,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-216284000.0,"depreciationAndCashflowFromOperatingActivities":44157000.0,"cashFlowFromInvestingActivities":-13465000.0,"cashFlowFromFinancialActivities":1004126000.0,"changesInCashAndCashEquivalents":767425000.0,"列1":"asr","submitDate":"2021\/3\/23","stockCode":4576,"accountingYear":"第23期（自　2020年１月１日　至　2020年12月31日）","accountingYearStart":"2020\/1\/1","accountingYearEnd":"2020\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E22024","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":34,"settlementDate":"2022\/12\/31","submitterName":"株式会社デ・ウエスタン・セラピテクス研究所","submitterNameEnglish":"D.Western Therapeutics Institute, Inc.","submitterNameKana":"カブシキガイシャデウエスタンセラピテクスケンキュウジョ","location":"名古屋市中区錦一丁目１８番１１号","industory":"医薬品","corporateNumber":5180000000000.0},{"edinetCode":"E22024","endDate":"2021\/3\/31","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.804,"cashAndCashEquivalents":null,"assets":2657091000.0,"currentAssets":2433828000.0,"fixedAsset":223263000.0,"tangibleFixedAssets":4667000.0,"intangibleFixedAssets":197723000.0,"investmentAndOtherAssets":20872000.0,"liabilities":517819000.0,"currentLiabilities":183819000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":120000000.0,"fixedLiabilities":334000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":310000000.0,"netAsset":2139271000.0,"capitalStock":2136579000.0,"capital":565244000.0,"capitalSurplus":2663959000.0,"accumulatedEarnings":-1092624000.0,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":89688000.0,"costOfSales":3916000.0,"grossProfit":85771000.0,"sgaExpenses":136576000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":65574000.0,"operatingIncome":-50805000.0,"nonOperatingIncome":11190000.0,"nonOperatingExpenses":1330000.0,"interestExpense":1216000.0,"ordinaryProfit":-40944000.0,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":-40944000.0,"incomeTaxes":398000.0,"netIncome":-41343000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-41343000.0,"comprehensiveIncome":-41343000.0,"eps":-1.41,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2021\/5\/13","stockCode":4576,"accountingYear":null,"accountingYearStart":"2021\/1\/1","accountingYearEnd":"2021\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E22024","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":34,"settlementDate":"2022\/12\/31","submitterName":"株式会社デ・ウエスタン・セラピテクス研究所","submitterNameEnglish":"D.Western Therapeutics Institute, Inc.","submitterNameKana":"カブシキガイシャデウエスタンセラピテクスケンキュウジョ","location":"名古屋市中区錦一丁目１８番１１号","industory":"医薬品","corporateNumber":5180000000000.0},{"edinetCode":"E22024","endDate":"2021\/6\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":9077082.0,"sharesOwendPercent":0.3091,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.81,"cashAndCashEquivalents":2100319000.0,"assets":2604424000.0,"currentAssets":2288511000.0,"fixedAsset":315913000.0,"tangibleFixedAssets":4194000.0,"intangibleFixedAssets":187763000.0,"investmentAndOtherAssets":123954000.0,"liabilities":490954000.0,"currentLiabilities":186954000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":120000000.0,"fixedLiabilities":304000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":280000000.0,"netAsset":2113469000.0,"capitalStock":2110777000.0,"capital":573159000.0,"capitalSurplus":2671874000.0,"accumulatedEarnings":-1134256000.0,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":201594000.0,"costOfSales":9137000.0,"grossProfit":192457000.0,"sgaExpenses":283682000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":152066000.0,"operatingIncome":-91225000.0,"nonOperatingIncome":11595000.0,"nonOperatingExpenses":2548000.0,"interestExpense":2366000.0,"ordinaryProfit":-82178000.0,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":-82178000.0,"incomeTaxes":797000.0,"netIncome":-82975000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-82975000.0,"comprehensiveIncome":-82975000.0,"eps":-2.83,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-74681000.0,"depreciationAndCashflowFromOperatingActivities":22333000.0,"cashFlowFromInvestingActivities":-100007000.0,"cashFlowFromFinancialActivities":-43379000.0,"changesInCashAndCashEquivalents":-207890000.0,"列1":"q2r","submitDate":"2021\/8\/10","stockCode":4576,"accountingYear":null,"accountingYearStart":"2021\/1\/1","accountingYearEnd":"2021\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E22024","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":34,"settlementDate":"2022\/12\/31","submitterName":"株式会社デ・ウエスタン・セラピテクス研究所","submitterNameEnglish":"D.Western Therapeutics Institute, Inc.","submitterNameKana":"カブシキガイシャデウエスタンセラピテクスケンキュウジョ","location":"名古屋市中区錦一丁目１８番１１号","industory":"医薬品","corporateNumber":5180000000000.0},{"edinetCode":"E22024","endDate":"2021\/9\/30","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.802,"cashAndCashEquivalents":null,"assets":2558979000.0,"currentAssets":2246377000.0,"fixedAsset":312602000.0,"tangibleFixedAssets":5252000.0,"intangibleFixedAssets":177191000.0,"investmentAndOtherAssets":130158000.0,"liabilities":469646000.0,"currentLiabilities":200408000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":124762000.0,"fixedLiabilities":269238000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":245238000.0,"netAsset":2089333000.0,"capitalStock":2051366000.0,"capital":573159000.0,"capitalSurplus":2631398000.0,"accumulatedEarnings":-1153191000.0,"treasuryStock":null,"valuationAndConversionAdjustments":null,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":315893000.0,"costOfSales":14441000.0,"grossProfit":301451000.0,"sgaExpenses":415820000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":228125000.0,"operatingIncome":-114369000.0,"nonOperatingIncome":13255000.0,"nonOperatingExpenses":4801000.0,"interestExpense":3440000.0,"ordinaryProfit":-105915000.0,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":-105915000.0,"incomeTaxes":1196000.0,"netIncome":-107112000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-101910000.0,"comprehensiveIncome":-107112000.0,"eps":-3.48,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2021\/11\/12","stockCode":4576,"accountingYear":null,"accountingYearStart":"2021\/1\/1","accountingYearEnd":"2021\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E22024","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"無","capital3":34,"settlementDate":"2022\/12\/31","submitterName":"株式会社デ・ウエスタン・セラピテクス研究所","submitterNameEnglish":"D.Western Therapeutics Institute, Inc.","submitterNameKana":"カブシキガイシャデウエスタンセラピテクスケンキュウジョ","location":"名古屋市中区錦一丁目１８番１１号","industory":"医薬品","corporateNumber":5180000000000.0}]